Results 161 to 170 of about 1,593,167 (326)
Emerging role of ARHGAP29 in melanoma cell phenotype switching
This study gives first insights into the role of ARHGAP29 in malignant melanoma. ARHGAP29 was revealed to be connected to tumor cell plasticity, promoting a mesenchymal‐like, invasive phenotype and driving tumor progression. Further, it modulates cell spreading by influencing RhoA/ROCK signaling and affects SMAD2 activity. Rho GTPase‐activating protein
Beatrice Charlotte Tröster +3 more
wiley +1 more source
Structural optimization and performance analysis of the cable-driven fine adjustment mechanism for the new FAST feed cabin. [PDF]
Zhang L, Sun J, Jiang P, Li H.
europepmc +1 more source
In this exploratory study, we investigated the relationship between the gut microbiota and outcome in patients with metastatic hormone receptor‐positive breast cancer, treated in a randomized clinical trial with chemotherapy alone or chemotherapy in combination with immune checkpoint blockade.
Andreas Ullern +7 more
wiley +1 more source
An ns-3 Evaluation Framework for Receiver-Initiated MAC Protocols with Configurable Enhancement Modules Across Various Network Scenarios. [PDF]
Murata T, Sakamoto S, Kawanami T.
europepmc +1 more source
Moho and LAB below the Western Alps from P and S Receiver Function analysis and joint inversion
Caterina Montuori +5 more
openalex +1 more source
This study investigated how PYCR1 inhibition in bone marrow stromal cells (BMSCs) indirectly affects multiple myeloma (MM) cell metabolism and viability. Culturing MM cells in conditioned medium from PYCR1‐silenced BMSCs impaired oxidative phosphorylation and increased sensitivity to bortezomib.
Inge Oudaert +13 more
wiley +1 more source
GNSS Spoofing Detection via Self-Consistent Verification of Receiver's Clock State. [PDF]
Chen Y +10 more
europepmc +1 more source
Conditional Diffusion Model-Enabled Scenario-Specific Neural Receivers for Superimposed Pilot Schemes [PDF]
Xingyu Zhou +6 more
openalex +1 more source
Following high dose rate brachytherapy (HDR‐BT) for hepatocellular carcinoma (HCC), patients were classified as responders and nonresponders. Post‐therapy serum induced increased BrdU incorporation and Cyclin E expression of Huh7 and HepG2 cells in nonresponders, but decreased levels in responders.
Lukas Salvermoser +14 more
wiley +1 more source

